FDA approves Atebrioz for fibrodysplasia ossificans progressiva in adults and pediatric patients
INCY•The FDA approved Atebrioz (zilurgisertib) for adults and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva. The recommended dosage is 100 mg once daily.
1. FDA approval
The FDA approved Atebrioz (zilurgisertib) for fibrodysplasia ossificans progressiva in adults and pediatric patients aged 12 years and older. The recommended dosage is 100 mg once daily.
